Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jiangsu Atom Bio Begins Global Phase IIb/III Trial of Gout Treatment

publication date: Oct 9, 2023

Jiangsu Atom Bioscience has dosed the first patient in a Phase IIb/III trial of its lead drug, ABP-671, a novel orally administered URAT1 inhibitor aimed at treating chronic gout. By reducing the reabsorption of uric acid in the kidneys, ABP-671 increases the excretion of uric acid. The multicenter, randomized, double-blind trial will enroll 580 patients globally, including the US. Part I will evaluate the safety and efficacy of ABP-671 at different doses with results available by the end of 2024. Part II will be a confirmatory study. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here